AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28469486
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate with single dose of Calcium Gluconate (SBCG1)
Trial: 28469486
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate with double dose of Calcium Gluconate (SBCG2)
Trial: 28470815
Drug: On-treatment virologic
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On-treatment virologic failure
Trial: 28471286
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICSs) adherence measured by a 4-item self-report questionnaire
Trial: 28471286
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICSs) adherence measured by a single question (SQ)
Trial: 28471286
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICSs) adherence measured by medication possession ratio (MPR)
Trial: 28472366
Drug: Enzalutamide or
RxNorm normalized name: enzalutamide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzalutamide or abiraterone in chemotherapy-naïve patients
Trial: 28472487
Drug: 11-oxygenated steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-oxygenated steroids (11OHA4, 11OHT, 11ketoT, 11ketoA4)
Trial: 28472509
Drug: Temozolomide (TMZ)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) 200 mg/m2 × 5/28 day for 6 cycles followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT).
Trial: 28472509
Drug: HDC (thiotepa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDC (thiotepa 250 mg/m2/day × 3 days, then busulfan 3.2 mg/kg/day × 3 days) followed by ASCT.
Trial: 28472928
Drug: Pre-adherence preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-adherence preparation
Trial: 28473851
Drug: Levothyroxine Replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine Replacement Therapy
Trial: 28475354
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of glucose with insulin
Trial: 28475354
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition containing amino acids
Trial: 28475354
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of amino acids in critically ill mice
Trial: 28476136
Drug: Supervised group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised group exercise twice weekly for 12 weeks
Trial: 28476148
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual (control group) with a leaflet about depression.
Trial: 28476440
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab (375 mg/m2)
Trial: 28476913
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant insertion
Trial: 28476913
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant insertion
Trial: 28476931
Drug: Genetic variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic variant rs11014566 (G allele)
Trial: 28477061
Drug: Telaprevir in
RxNorm normalized name: Product containing telaprevir in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir in combination with peg-interferon and ribavirin (Peg-IFN/RBV)
Trial: 28478485
Drug: Radium-223 dichloride
RxNorm normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium-223 dichloride (55 kBq/kg body weight every 4 weeks for up to six injections)
Trial: 28478485
Drug: Radium-223 dichloride
RxNorm normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium-223 dichloride (initial single injection of 110 kBq/kg BW followed by up to five injections of 55 kBq/kg BW Q4W)
Trial: 28478485
Drug: Radium-223 dichloride
RxNorm normalized name: radium-223 dichloride
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium-223 dichloride (overall treatment)
Trial: 28480334
Drug: 4-valent HPV
RxNorm normalized name: HPV, bivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-valent HPV (4vHPV) vaccine
Trial: 28482144
Drug: Canakinumab 300
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 300 mg subcutaneously every 6 weeks during period 1 (P1)
Trial: 28482144
Drug: Canakinumab treatment
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab treatment during period 1 (P1)
Trial: 28482144
Drug: Canakinumab treatment
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab treatment during period 2 (P2)
Trial: 28482146
Drug: Subcutaneous adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous adipose tissue (SAT) measurement
Trial: 28482908
Drug: Adenovirus-specific T
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus-specific T cell (ADV-VST) infusion from HSCT donor or third party haploidentical donor
Trial: 28482908
Drug: Adenovirus-specific T
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenovirus-specific T cell (ADV-VST) infusion
Trial: 28483716
Drug: Prophylactic donor
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease (MRD) test and graft-versus-host disease (GVHD)-guided multiple DLIs.
Trial: 28483828
Drug: Salt added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt added in home food preparation
Trial: 28483828
Drug: Home tap
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home tap water consumed as a beverage and dietary supplement and nonprescription antacids
Trial: 28483965
Drug: Efavirenz (EFV)
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) at a dose of 25 mg/kg of body weight/day
Trial: 28484421
Drug: PCTus-based antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCTus-based antibiotic therapy guidance in addition to stroke unit care
Trial: 28484650
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive surgical treatment (keyhole approach)
Trial: 28484650
Drug: Gold standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold standard surgical treatment (not specified)
Trial: 28484958
Drug: Diuretic resistance
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic resistance defined by fractional sodium excretion (FeNa) <0.2%
Trial: 28484958
Drug: Diuretic resistance
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic resistance defined by urinary sodium <50 meq/L
Trial: 28484958
Drug: Diuretic resistance
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic resistance defined by urinary Na/K ratio <1.0
Trial: 28484958
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of definitions of diuretic resistance
Trial: 28485816
Drug: Classic systemic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic systemic therapies
Trial: 28487034
Drug: Multiple biomarker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple biomarker score including NT-proBNP, kidney injury molecule-1, osteopontin, and tissue inhibitor of metalloproteinase-1
Trial: 28487491
Drug: Regorafenib 160
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 160 mg orally daily on days 1-21 of a 28-day cycle
Trial: 29095678
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for up to 24 months
Trial: 28489732
Drug: NVP prophylactic
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP prophylactic dosing (WHO weight-band recommendations)
Trial: 28489732
Drug: NVP therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVP therapeutic dosing (6 mg/kg twice daily)
Trial: 28494506
Drug: Hypomethylating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypomethylating agents (HMA) including decitabine (DAC) and azacitidine (AZA) after induction/consolidation with fludarabine, cytarabine, and G-CSF (FLAG) with low dose gemtuzumab or idarubicin.
Trial: 28494798
Drug: chronic low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chronic low-dose step up protocol with recombinant human FSH (rhFSH)
Trial: 28495029
Drug: Delafloxacin 450
RxNorm normalized name: delafloxacin 450 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 450 mg every 12 hours from days 3 to 8
Trial: 28495029
Drug: Midazolam 5
RxNorm normalized name: midazolam 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 5 mg oral dose on days 1 and 8
Trial: 28495639
Drug: CPI-613 in
RxNorm normalized name: CPI-1205
DrugBank: CPI-1205 (DB14581)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPI-613 in combination with modified FOLFIRINOX (oxaliplatin at 65 mg/m², leucovorin, irinotecan, and fluorouracil)
Trial: 28495794
Drug: Complete or
RxNorm normalized name: Canker Complete Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after enrollment
Trial: 28497258
Drug: Veliparib administered
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib administered orally at doses ranging from 10 to 80 mg twice daily on days 1-7
Trial: 28497258
Drug: Temozolomide administered
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide administered orally at 150-200 mg/m2
Trial: 28497757
Drug: Veliparib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib (400 mg twice daily) combined with capecitabine (825 mg/m2) and radiotherapy
Trial: 28498618
Drug: CDCA1 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA1 peptide vaccination (1.0 mg)
Trial: 28498618
Drug: CDCA1 peptide
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA1 peptide vaccination (3.0 mg)
Trial: 28498880
Drug: TPF induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF induction chemotherapy (30 mg/m2 docetaxel, 40 mg/m2 cisplatin, 2000 mg/m2 fluorouracil per week)
Trial: 28499389
Drug: Tumor resection
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor resection and combined radio-chemotherapy
Trial: 28501811
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment with advanced virtual stenting technique and porous media method for haemodynamic simulations.
Trial: 28501909
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist therapy (VKA)
Trial: 28502418
Drug: Budesonide/formoterol (fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (fixed-dose strategy)
Trial: 28502892
Drug: Adequate initial
RxNorm normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate initial antibiotic therapy
Trial: 28503190
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of essential amino acids (EAA)
Trial: 28503190
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of essential amino acids (EAA) with chloroquine (CQ)
Trial: 28504860
Drug: Allogeneic bone
RxNorm normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) expanded in vitro, dose 1-2 × 10^6 cells/kg
Trial: 28504996
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 7 mL/kg administered for 30 minutes after opening the thoracic cavity.
Trial: 28505327
Drug: SAHA (5-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAHA (5-day intraperitoneal administration)
Trial: 28506306
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment during the study period
Trial: 28506390
Drug: OM3-CA 4
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM3-CA 4 g once daily for 13 days with rosuvastatin 40 mg (single dose) co-administered with the 11th dose.
Trial: 28506390
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg plus acetylsalicylic acid 81 mg daily for 14 days with or without OM3-CA.
Trial: 28506516
Drug: 5 doses
RxNorm normalized name: diazepam
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 doses of DTaP vaccine
Trial: 28506516
Drug: Any DTaP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any DTaP vaccine
Trial: 28507113
Drug: Binuclear Cyclopalladated
RxNorm normalized name: Glycerin 0.04 g in 1 g VAGINAL GEL [Inclear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binuclear Cyclopalladated Compound Therapy
Trial: 28508253
Drug: DEBDOX treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEBDOX treatment
Trial: 28508945
Drug: Cryoablation combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryoablation combined with allogenic NK cell immunotherapy
Trial: 28510797
Drug: Morphine-3-Glucuronide (M3G)
RxNorm normalized name: MENTHOL GLUCURONIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-3-Glucuronide (M3G)
Trial: 28510797
Drug: Morphine-6-Glucuronide (M6G)
RxNorm normalized name: MENTHOL GLUCURONIDE
DrugBank: Morphine glucuronide (DB06409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-6-Glucuronide (M6G)
Trial: 28511673
Drug: Vismodegib 150
RxNorm normalized name: vismodegib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib 150 mg orally once daily until disease progression or intolerable toxicity
Trial: 28511692
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg paricalcitol daily
Trial: 28511692
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg paricalcitol daily
Trial: 28511709
Drug: Tandem high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) after nine cycles of induction chemotherapy.
Trial: 28514929
Drug: Image-guided accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Image-guided accelerated hypofractionated proton therapy (AHPT) at 70Gy(RBE) in 28 fractions for low-risk disease
Trial: 28514929
Drug: Image-guided accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Image-guided accelerated hypofractionated proton therapy (AHPT) at 72.5Gy(RBE) in 29 fractions for intermediate-risk disease
Trial: 28514929
Drug: Image-guided accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Image-guided accelerated hypofractionated proton therapy (AHPT)
Trial: 28515269
Drug: Seal oil
RxNorm normalized name: seal oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seal oil omega-3 polyunsaturated fatty acids (ω-3 PUFA) supplementation (10 mL·d)
Trial: 28522574
Drug: Nilotinib, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib, oral administration, monitored within three hours of administration.
Trial: 28522574
Drug: Nilotinib, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib, oral administration, monitored within seven days.
Trial: 28523161
Drug: Heparin sodium
RxNorm normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin sodium 5,000 U, bid preoperatively upon admission
Trial: 28523482
Drug: Physician-driven titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-driven titration of BIAsp 30
Trial: 28523582
Drug: Integrin-targeting radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrin-targeting radiopharmaceuticals (200 MBq injection)
Trial: 28525370
Drug: Metronomic vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic vinorelbine (60 mg on Day 1, 30 mg on Day 2, and 60 mg on Day 4 weekly until progression)
Trial: 28526489
Drug: Intravitreous injection
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous injection of AAV2-sFLT01
Trial: 28526542
Drug: Diabetes mellitus
RxNorm normalized name: diagnostic,monitoring agents for diabetes mellitus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes mellitus treated with oral medication or insulin
Trial: 28527133
Drug: TAK-264 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-264 1.8 mg/kg
Trial: 28528010
Drug: Sustained-Release Bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sustained-Release Bimatoprost Ocular Ring
Trial: 28528875
Drug: Central augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central augmentation pressure
Trial: 28528917
Drug: Pazopanib 600mg
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pazopanib 600mg daily p.o. and metronomic cyclophosphamide 50mg daily p.o.
Trial: 28529313
Drug: Histamine dihydrochloride
RxNorm normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine dihydrochloride and low-dose IL-2
Trial: 28529748
Drug: Local modulated
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local modulated electro-hyperthermia (mEHT) combined with traditional Chinese medicine (TCM) 'Shi Pi' herbal decoction, applied for 60 min every second day for 4 weeks (14 sessions); TCM decoction administered orally at 400 ml daily.
Trial: 28529748
Drug: Standard intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intraperitoneal chemoinfusion (IPCI) with cisplatin (30-60 mg) and fluorouracil (500-600 mg/m2).
Trial: 28531175
Drug: High-dose liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose liposomal amphotericin B (L-AmB) 10 mg/kg/week for 2 weeks
Trial: 28531305
Drug: IAA (Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAA (Insulin Autoantibodies)
Trial: 28531455
Drug: Control (Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Cream of Rice)
Trial: 28531881
Drug: CAP7.1 (45,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP7.1 (45, 90, 150, and 200 mg/m²)
Trial: 28531881
Drug: CAP7.1 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP7.1 (intravenous infusion for 5 consecutive days)
Trial: 28533916
Drug: Intravenous pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pantoprazole 1 mg/kg once daily until no longer needing mechanical ventilation
Trial: 28535181
Drug: Everolimus 5
RxNorm normalized name: everolimus 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 5 mg daily combined with paclitaxel 175 mg/m2 and carboplatin AUC 5 every 3 weeks for a maximum of four cycles followed by maintenance everolimus 5 mg daily until progression
Trial: 28535298
Drug: Ledipasvir-Sofosbuvir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir-Sofosbuvir plus Ribavirin (90 mg and 400 mg) for 12 weeks